Literature DB >> 30506507

Potential bio-protective effect of copper compounds: mimicking SOD and peroxidases enzymes and inhibiting acid phosphatase as a target for anti-osteoporotic chemotherapeutics.

Nancy Martini1, Juliana E Parente1, Franco D Alessandro1, Marilin Rey2, Alberto Rizzi2, Patricia A M Williams1, Evelina G Ferrer3.   

Abstract

Copper complexes with transformed methimazole ligand have been synthesized and characterized by elemental analysis, conductivity measurements, thermogravimetric analysis, EPR, FTIR and UV-Vis spectroscopies. Results support their stoichiometries and geometrical structures: [Cu(C4H5N2S)2Cl2]·2H2O(1), [Cu(C8H10N4S)SO4H2O](2) and [Cu(C8H10N4S)SO4](3). ((C4H5N2)2S: bis(l-methylimidazol-2-yl)sulfide; (C4H5N2S)2 = Bis[bis(l-methylimidazol-2-yl)disulfide]) Concurrently, the structurally distinct soluble species corresponding to complexes (1) and (2) were subsequently used in an in vitro investigation of their potential biological properties. In view of their possible pharmaceutical activity, the complexes were in vitro evaluated as phosphatase acid inhibitors. Their radical bio-protective effects were also studied measuring the effect against DPPH• and O2•- radicals. Additional catalytic properties as peroxidase mimics were evaluated using Michaelis-Menten kinetic model by means of phenol red and pyrogallol assays. The complexes exhibited catalytic bromination activity and the ability to oxidize pyrogallol substrate indicating that they can be considered as functional models. The relationships between the structures and the in vitro biological activities have also been considered. Serum protein albumin has attracted the greatest interest as drug carrier and the affinity of biological/pharmaceutical compound is relevant to the development of new medicine. In that sense, interaction studies by fluorescence and EPR spectroscopies were performed showing the binding capacity of the complexes.

Entities:  

Keywords:  Copper complexes; Peroxidase-like activity; Phosphatase inhibition; Superoxide dismutase activity

Mesh:

Substances:

Year:  2018        PMID: 30506507     DOI: 10.1007/s11033-018-4542-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  26 in total

1.  Metal complexes as enzyme inhibitors.

Authors:  A Y Louie; T J Meade
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  EasySpin, a comprehensive software package for spectral simulation and analysis in EPR.

Authors:  Stefan Stoll; Arthur Schweiger
Journal:  J Magn Reson       Date:  2005-09-26       Impact factor: 2.229

3.  Metal mediated C-S rupture of heterocyclic thioamides: in situ generation of 2,2'-thio-di-2-imidazoline, 1,1'-dimethyl-2,2'-di-imidazolylsulfide, SO4(2-) and their variable coordination to Cu(II).

Authors:  Tarlok S Lobana; Razia Sultana; Geeta Hundal; Ray J Butcher
Journal:  Dalton Trans       Date:  2010-07-30       Impact factor: 4.390

4.  Structure-DPPH* scavenging activity relationships: parallel study of catechol and guaiacol acid derivatives.

Authors:  Stella A Ordoudi; Maria Z Tsimidou; Anastasios P Vafiadis; Evangelos G Bakalbassis
Journal:  J Agric Food Chem       Date:  2006-08-09       Impact factor: 5.279

Review 5.  Clinical impact of serum proteins on drug delivery.

Authors:  Felix Kratz; Bakheet Elsadek
Journal:  J Control Release       Date:  2011-12-01       Impact factor: 9.776

6.  Copper(II) complexes of methimazole, an anti Grave's disease drug. Synthesis, characterization and its potential biological behavior as alkaline phosphatase inhibitor.

Authors:  Nora M Urquiza; Silvia G Manca; María A Moyano; Raquel Arrieta Dellmans; Luis Lezama; Teófilo Rojo; Luciana G Naso; Patricia A M Williams; Evelina G Ferrer
Journal:  Biometals       Date:  2009-12-11       Impact factor: 2.949

7.  Inhibition of acid, alkaline, and tyrosine (PTP1B) phosphatases by novel vanadium complexes.

Authors:  Craig C McLauchlan; Jaqueline D Hooker; Marjorie A Jones; Zaneta Dymon; Emily A Backhus; Bradley A Greiner; Nicole A Dorner; Mary A Youkhana; Lisa M Manus
Journal:  J Inorg Biochem       Date:  2009-12-11       Impact factor: 4.155

8.  Identification of purple acid phosphatase inhibitors by fragment-based screening: promising new leads for osteoporosis therapeutics.

Authors:  Daniel Feder; Waleed M Hussein; Daniel J Clayton; Meng-Wei Kan; Gerhard Schenk; Ross P McGeary; Luke W Guddat
Journal:  Chem Biol Drug Des       Date:  2012-09-03       Impact factor: 2.817

9.  Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases.

Authors:  Mohsen Valizadeh; Gerhard Schenk; Kevin Nash; Geoff W Oddie; Luke W Guddat; David A Hume; John de Jersey; Terrence R Burke; Susan Hamilton
Journal:  Arch Biochem Biophys       Date:  2004-04-15       Impact factor: 4.013

10.  Mimic models of peroxidase--kinetic studies of the catalytic oxidation of hydroquinone by H2O2.

Authors:  Xiang-Guang Meng; Yong Guo; Chang-Wei Hu; Xian-Cheng Zeng
Journal:  J Inorg Biochem       Date:  2004-12       Impact factor: 4.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.